Overview
Everest Organics Ltd is primarily engaged in the manufacturing of Active Pharmaceutical Ingredients and intermediaries, with operations commencing in 1993.
The company had set up a plant in Andhra Pradesh focusing initially on bulk drugs and formulations, with a public issue in 1995 to fund its growth.
In 1996, Everest Organics expanded its production capabilities with increased capacity for ciprofloxacin and benzimidazole, illustrating strategic adjustments to market conditions.
Despite initial plans for PHPG manufacturing, the company shifted focus towards enhancing ciprofloxacin production due to changing market dynamics.
Through strategic investments, the company introduced new products like Esomeprazole Magnesium in 2007-08, highlighting innovation in its product portfolio.
- Sector
Pharmaceuticals
- Industry
Pharmaceuticals - Indian - Bulk Drugs
- Market Cap
297 Cr
- Volatility
Low Risk
- P/E Ratio
50.4
- Industry P/E
56.7
- PEG Ratio
—
- P/B Ratio
4.1
- 52W High
536.40
- 52W Low
224.80
Financial Ratios
Sales CAGR
- 1Y
- -19.14%
- 3Y
- -7.47%
- 5Y
- -0.78%
- 10Y
- 5.94%
Profit CAGR
- 1Y
- -1021.43%
- 3Y
- —
- 5Y
- —
- 10Y
- —
ROE
- TTM
- —
- 3Y
- -0.82%
- 5Y
- 5.30%
- 10Y
- 9.87%
ROCE
- TTM
- —
- 3Y
- 5.30%
- 5Y
- 10.86%
- 10Y
- 16.75%
Technicals
Oscillators
Neutral
Bearish
3
Neutral
6
Bullish
5
Overall
Bearish
Bearish
30
Neutral
6
Bullish
10
Moving Averages
Bearish
Bearish
27
Neutral
0
Bullish
5
Forecasts
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
